'Biosimilar V. Biosimilar' Patent Case May Be First Of Many

Law360 (March 4, 2019, 2:36 PM EST) -- On Jan. 24, 2019, Coherus BioSciences Inc. filed a complaint against Amgen Inc. in the U.S. District Court for the District of Delaware. alleging infringement of three related patents directed to pharmaceutical formulations of adalimumab, the active ingredient in AbbVie’s blockbuster biologic Humira.

This case is unique in that it pits one biosimilar developer against another. This “biosimilar v. biosimilar” patent litigation appears to be the first of its kind in the United States, and could potentially signal a new wave of litigations of which biosimilar developers should be wary.

Yet the idea of patent disputes between makers of follow-on drugs...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS